Treatment in CARD eligible metastatic castration resistant prostate cancer (mCRPC) patients according to the status of germline HRR mutations: Cabazitaxel (CBZ) vs enzalutamide/abiraterone

Simple item page
dc.conference.dateSEP 19-OCT 18, 2020
dc.conference.titleESMO Virtual Congress
dc.contributor.authorLlacer Perez, C.
dc.contributor.authorRomero Laorden, N.
dc.contributor.authorLozano Mejorada, R.
dc.contributor.authorPiulats, J. M.
dc.contributor.authorPuente, J.
dc.contributor.authorLorente Estelles, D.
dc.contributor.authorMedina, A.
dc.contributor.authorCattrini, C.
dc.contributor.authorVitrone, F. M.
dc.contributor.authorAlmagro, E.
dc.contributor.authorBorrega Garcia, P.
dc.contributor.authorLainez, N.
dc.contributor.authorRivera, L.
dc.contributor.authorVillatoro, R.
dc.contributor.authorHernandez, A.
dc.contributor.authorRodriguez-Vida, A.
dc.contributor.authorLopez-Casas, P. P.
dc.contributor.authorGallardo, E.
dc.contributor.authorCastro Marcos, E.
dc.contributor.authorOlmos Hidalgo, D.
dc.contributor.authoraffiliation[Llacer Perez, C.] Hosp Univ Virgen de la Victoria & Reg, Inst Invest Biomed Malaga IBIMA, Med Oncol Dept, CNIO IBIMA Unit, Malaga, Spain
dc.contributor.authoraffiliation[Romero Laorden, N.] CNIO Ctr Nacl Invest Oncol, Prostate Canc, Madrid, Spain
dc.contributor.authoraffiliation[Lozano Mejorada, R.] CNIO Ctr Nacl Invest Oncol, Prostate Canc Clin Res Unit, Madrid, Spain
dc.contributor.authoraffiliation[Cattrini, C.] CNIO Ctr Nacl Invest Oncol, Prostate Canc Clin Res Unit, Madrid, Spain
dc.contributor.authoraffiliation[Rivera, L.] CNIO Ctr Nacl Invest Oncol, Prostate Canc Clin Res Unit, Madrid, Spain
dc.contributor.authoraffiliation[Lopez-Casas, P. P.] CNIO Ctr Nacl Invest Oncol, Prostate Canc Clin Res Unit, Madrid, Spain
dc.contributor.authoraffiliation[Piulats, J. M.] Catalan Inst Oncol, Med Oncol, Barcelona, Spain
dc.contributor.authoraffiliation[Puente, J.] Hosp Clin Univ San Carlos, Dept Med Oncol, Madrid, Spain
dc.contributor.authoraffiliation[Lorente Estelles, D.] Hosp Gen Univ Castellon, Med Oncol Dept, Castellon de La Plana, Spain
dc.contributor.authoraffiliation[Medina, A.] Ctr Oncol Galicia, Med Oncol Dept, La Coruna, Spain
dc.contributor.authoraffiliation[Vitrone, F. M.] CNIO Ctr Nacl Invest Oncol, Dept Med Oncol, Madrid, Spain
dc.contributor.authoraffiliation[Almagro, E.] Hosp Univ Quironsalud Madrid, Med Oncol Dept, Pozuelo De Alarcon, Spain
dc.contributor.authoraffiliation[Borrega Garcia, P.] Hosp San Pedro de Alcantara, Med Oncol Dept, Caceres, Spain
dc.contributor.authoraffiliation[Lainez, N.] Complejo Hosp Navarra, Med Oncol Dept, Pamplona, Spain
dc.contributor.authoraffiliation[Villatoro, R.] Hosp Univ Costa del Sol, Med Oncol Dept, Marbella, Spain
dc.contributor.authoraffiliation[Hernandez, A.] Inst Oncol, Onkologikoa, Donostia San Sebastian, Spain
dc.contributor.authoraffiliation[Rodriguez-Vida, A.] Hosp Mar, Med Oncol Dept, Barcelona, Spain
dc.contributor.authoraffiliation[Gallardo, E.] Univ Autonoma Barcelona, Med Oncol Dept, Parc Tauli Hosp Univ, Inst Invest & Innovacio Parc Tauli I3PT, Barcelona, Spain
dc.contributor.authoraffiliation[Castro Marcos, E.] Hosp Univ Virgen de la Victoria, Med Oncol, Malaga, Spain
dc.contributor.authoraffiliation[Castro Marcos, E.] Inst Invest Biomed Malaga, Malaga, Spain
dc.contributor.authoraffiliation[Olmos Hidalgo, D.] CNIO Spanish Natl Canc Ctr, Prostate Canc Clin Res Unit, Madrid, Spain
dc.date.accessioned2025-01-07T15:22:29Z
dc.date.available2025-01-07T15:22:29Z
dc.date.issued2020-09-01
dc.identifier.doi10.1016/j.annonc.2020.08.887
dc.identifier.essn1569-8041
dc.identifier.issn0923-7534
dc.identifier.unpaywallURLhttp://www.annalsofoncology.org/article/S092375342040883X/pdf
dc.identifier.urihttps://hdl.handle.net/10668/27082
dc.identifier.wosID573469100625
dc.issue.number4
dc.journal.titleAnnals of oncology
dc.journal.titleabbreviationAnn. oncol.
dc.language.isoen
dc.organizationSAS - Hospital Universitario Virgen de la Victoria
dc.organizationSAS - Hospital Universitario Virgen de la Victoria
dc.organizationSAS - Hospital Costa del Sol
dc.organizationSAS - Hospital Universitario Regional de Málaga
dc.organizationInstituto de Investigación Biomédica de Málaga - Plataforma Bionand (IBIMA)
dc.page.numberS518-S519
dc.publisherElsevier
dc.rights.accessRightsopen access
dc.titleTreatment in CARD eligible metastatic castration resistant prostate cancer (mCRPC) patients according to the status of germline HRR mutations: Cabazitaxel (CBZ) vs enzalutamide/abiraterone
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number31
dc.wostypeMeeting Abstract

Files

Collections

SAS - Hospital Universitario Virgen de la Victoria
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (FIMABIS)
Instituto de Investigación Biomédica de Málaga - Plataforma Bionand (IBIMA)
SAS - Hospital Costa del Sol

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía